This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Carl Muschenheim, M.D.

AMA Arch Intern Med. 1957;99(5):673-677.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It is somewhat less than five years since the first publications on isoniazid appeared in April, 1952,^1-6 but this drug had then been under clinical investigation by two groups for more than half a year.^5,6 It is possible, therefore, to look back on a full five years of clinical experience.

The marked symptomatic benefit noticed and resulting conspicuous exuberance displayed by many of the patients first to receive the isonicotinic acid hydrazides followed more often from iproniazid than from isoniazid.⁷ Because of its lower toxicity and its equal, or very nearly equal, objective benefit, isoniazid itself has virtually displaced the isopropyl derivative. Its less dramatic, and perhaps somewhat slower effect caused some disappointment when isoniazid became generally available. An even more disturbing factor, however, was the in vitro demonstration of relatively early increased bacterial resistance in successive cultures of sputum. It was then expected by many clinicians . . . [Full Text PDF of this Article]

Author Affiliations
133 E. 64th St., New York

From the Department of Medicine, Cornell University Medical College, and the New York Hospital, New York, N. Y.

Footnotes
Accepted for publication Jan. 4, 1957.

Presented before 69th Meeting of the American Clinical and Climatological Association, Skytop, Pa., Nov. 1, 1956.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?